Parkell Desensitizer Gel

K191103 · Parkell, Inc. · EJK · Nov 22, 2019 · Dental

Device Facts

• Record ID: K191103
• Device Name: Parkell Desensitizer Gel
• Applicant: Parkell, Inc.
• Product Code: EJK · Dental
• Decision Date: Nov 22, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 872.3250
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Parkell® Desensitizer Gel is indicated for reduction of tooth hypersensitivity by the following treatments: - treatment of dentin exposed by toothbrush abrasion, periodontal disease, and/or acid erosion; - treatment of dentin after mechanical tooth cleaning, scaling, and/or root planning; - treatment of tooth hypersensitivity associated with bleaching: and - treatment of prepared dentin for fillings and/or prosthetic restorations.

Device Story

Parkell Desensitizer Gel treats dental hypersensitivity; applied to dentin via standard applicator brush. Device releases calcium and phosphate ions; stimulates hydroxyapatite formation on dentin surface and within dentinal tubules. Hardens post-application; forms mineral hydroxyapatite layer and plugs to occlude tubules. Used in dental clinic setting by dental professionals. Output is physical occlusion of tubules; reduces patient sensitivity to thermal or mechanical stimuli. Packaged in single-chamber syringe with snap-in tips.

Clinical Evidence

No clinical data provided. Substantial equivalence supported by bench testing, including biocompatibility (ISO 10993 series) and bioactivity analysis (ISO 23317:2014). Microshear bond strength testing demonstrated performance ≥15MPa, consistent with predicate.

Technological Characteristics

Composition: water, calcium phosphate-based fillers. Form: gel. Delivery: single-chamber syringe with applicator tips. Principle: chemical-induced hydroxyapatite formation and tubule occlusion. Biocompatibility: ISO 10993 compliant. Bioactivity: ISO 23317 compliant.

Indications for Use

Indicated for reduction of tooth hypersensitivity in patients with dentin exposure due to toothbrush abrasion, periodontal disease, acid erosion, or post-mechanical cleaning/scaling/root planing; hypersensitivity associated with bleaching; and prepared dentin for restorations.

Regulatory Classification

Identification

A calcium hydroxide cavity liner is a device material intended to be applied to the interior of a prepared cavity before insertion of restorative material, such as amalgam, to protect the pulp of a tooth.

Predicate Devices

• Teethmate Desensitizer (K131068)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

November 22, 2019

Parkell, Inc. David Mott Vice President - Legal, R&D, and Regulatory 300 Executive Drive Edgewood, New York 11717

Re: K191103

Trade/Device Name: Parkell Desensitizer Gel Regulation Number: 21 CFR 872.3250 Regulation Name: Calcium Hydroxide Cavity Liner Regulatory Class: Class II Product Code: EJK, LBH Dated: October 24, 2019 Received: October 25, 2019

Dear David Mott:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

for Srinivas Nandkumar, Ph.D. Acting Director DHT1B: Division of Dental Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K191103

Device Name Parkell® Desensitizer Gel

Indications for Use (Describe)

Parkell® Desensitizer Gel is indicated for reduction of tooth hypersensitivity by the following treatments:

- · treatment of dentin exposed by toothbrush abrasion, periodontal disease, and/or acid erosion;
- · treatment of dentin after mechanical tooth cleaning, scaling, and/or root planning;
- · treatment of tooth hypersensitivity associated with bleaching: and
- · treatment of prepared dentin for fillings and/or prosthetic restorations.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

| | <span> <svg height="15" width="15"> <path d="M2 2 L13 13 M13 2 L2 13" stroke="black" stroke-width="2"></path> </svg> </span> Prescription Use (Part 21 CFR 801 Subpart D) |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <span> <svg height="15" width="15"> <rect fill="white" height="15" stroke="black" stroke-width="1" width="15"></rect> </svg> </span> Over-The-Counter Use (21 CFR 801 Subpart C) |

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Parkell Inc. The logo is in black and white and features the word "parkell" in a bold, sans-serif font. To the right of "parkell" and slightly below is the word "inc." in a smaller, italicized font. The overall design is simple and professional.

# 510(k) Summary – K191103

#### 1. Submitter

Parkell, Inc. 300 Executive Drive Edgewood, NY 11717 Phone: [phone] Fax: [phone] [e-mail]

Contact Person: David Mott, Vice President - Legal & Regulatory Date of Initial Submission: April 24, 2019 Date of Submission of Final Revision: October 24, 2019

#### 2. Device

| Device Proprietary Name: | Parkell® desensitizer |
|--------------------------|--------------------------------|
| Common or Usual Name: | Tooth desensitizer |
| Classification Name: | Calcium hydroxide cavity liner |
| Regulation Number: | 21 CFR 872.3250 |
| Product Code: | EJK |
| Device Classification | II |

#### 3. Primary Predicate

Teethmate Desensitizer, K131068, Kuraray Noritake Dental Inc.

#### 4. Device Description

Parkell® Desensitizer Gel alleviates dental hypersensitivity at treatment sites. It is a gel which requires no mixing prior to use and which is applied to treatment sites using a standard applicator brush. Parkell® Desensitizer releases calcium and phosphate ions at the treatment site and stimulates hydroxyapatite formation on the surface of treated dentin and in dentinal tubules. In this manner, the Device hardens following application and forms a layer of mineral hydroxyapatite as well as hydroxyapatite plugs which occlude dentinal tubules, which results in the treatment of dental hypersensitivity.

Parkell® Desensitizer Gel is packaged in any standard single-chamber syringe. The syringe is accompanied by standard snap-in tips and standard applicator brushes.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Parkell Inc. The logo is in black and white and features the word "parkell" in a bold, sans-serif font. To the right of "parkell" and slightly below is the word "inc." in a smaller, italicized font. The logo is simple and professional.

#### 5. Indications for Use

Parkell® Desensitizer Gel is indicated for reduction of tooth hypersensitivity by the following treatments:

- treatment of dentin exposed by toothbrush abrasion, gingival recession, periodontal disease, and/or acid erosion;
- · treatment of dentin after mechanical tooth cleaning, scaling, and/or root planning;
- treatment of tooth hypersensitivity associated with bleaching; and
- treatment of prepared dentin for fillings and/or prosthetic restorations.

## 6. Comparison of Technological Characteristics

Information provided in this 510(k) submission demonstrates that Parkell® Desensitizer Gel is substantially equivalent to the Primary Predicate (Teethmate Desensitizer, K131068), in terms of the intended use and technological characteristics.

Any differences between the Device and the Primary Predicate, for purposes of this 510(k) submission, are of a minor nature as is demonstrated in Table 5-A and throughout this submission. Thus, this submission demonstrates the substantial equivalence between Parkell® desensitizer and the Primary Predicate. A brief comparison of Parkell® Desensitizer Gel to the Primary Predicate is provided below:

| Property | Parkell® Desensitizer Gel<br>(Parkell, Inc.) | Primary Predicate<br>Teethmate Desensitizer (K131068, Kuraray Noritake Dental Inc.) |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended uses | Parkell® Desensitizer Gel is indicated for reduction of tooth hypersensitivity by the following treatments: treatment of dentin exposed by toothbrush abrasion, gingival recession, periodontal disease, and/or acid erosion; treatment of dentin after mechanical tooth cleaning, scaling, and/or root planning; treatment of tooth hypersensitivity associated with bleaching; and treatment of prepared dentin for fillings and/or prosthetic restorations. | Teethmate Desensitizer is indicated for reduction of tooth hypersensitivity by the following treatments: treatment of dentin exposed by toothbrush abrasion, gingival recession, periodontal disease, and/or acid erosion; treatment of dentin after mechanical tooth cleaning, scaling, and/or root planning; treatment of tooth surface before and/or after bleaching; and treatment of prepared dentin for fillings and/or prosthetic restorations. |
| Classification Product Code | EJK | EJK |
| Regulation Number | 21 CFR 872.3250 | 21 CFR 872.3250 |
| Principle of operation | tooth desensitizer | tooth desensitizer |
| Material form | gel | powder/liquid |

## Table 5-A:

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for "parkell inc.". The word "parkell" is written in a bold, sans-serif font, with the letters closely spaced together. To the right of "parkell", the word "inc." is written in a smaller, italicized font. The logo is in black and white.

| | | Parkell® Desensitizer<br>Gel<br>(Parkell, Inc.) | Primary Predicate<br>Teethmate Desensitizer<br>(K131068, Kuraray) |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------------------------|
| Chemical composition | | water; calcium<br>phosphate-<br>based filler(s) | water; calcium<br>phosphate-<br>based filler(s) |
| Surface coverage of treated dentin | | yes | yes |
| Occludes dentinal tubules | | yes | yes |
| Microshear bond<br>strength to dentin of<br>resin-based bonding<br>agents following<br>pretreatment with<br>Device or Predicate<br>Device<br>(Pass/fail criteria of at<br>least about 15MPa) | Commercially-available<br>bonding agent #1<br>[self-etch mode] | ≥15MPa | ≥15MPa |
| | Commercially-available<br>bonding agent #1<br>[total-etch mode] | ≥15MPa | ≥15MPa |
| | Commercially-available<br>bonding agent #2<br>[self-etch mode] | ≥15MPa | ≥15MPa |

#### Table 5-A (continued):

As seen above, the differences between the subject and primary predicate devices are limited to materials of construction and material form. These technological differences do not raise issues with respect to substantial equivalence and are addressed by comparative performance data provided within this submission.

#### 7. Biocompatibility and Bench Data

An evaluation of biocompatibility was conducted on Parkell® desensitizer in accordance, e.g., with ISO10993-1:2009, ISO10993-5:2009, ISO10993-10:2010, ISO10993-11:2017, ISO10993-12: 2012, and the FDA Guidance, "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" (June 16, 2016). The conclusion of the evaluation is that Parkell® Desensitizer Gel is biocompatible. In addition, an evaluation of the bioactivity of Parkell® desensitizer was performed through analysis of treated dental tissue and via tests performed in accordance with ISO23317:2014.

#### 8. Clinical Performance Data

There was no clinical testing required to support the Device as the intended uses are equivalent to the Predicate Device. These types of devices have been on the market for many years with no reported adverse events. The non-clinical testing detailed in this submission supports the substantial equivalence of the Device.

#### 9. Statement of Substantial Equivalence:

The information provided above supports that Parkell® Desensitizer Gel is substantially equivalent to the Primary Predicate. Although minor differences in design and technology exist between the subject and primary predicate devices, the testing supports that these differences do not raise questions as to the substantial equivalence between the devices. Therefore, it is concluded that Parkell® Desensitizer Gel is substantially equivalent to the Primary Predicate.